000284822 001__ 284822
000284822 005__ 20240918104134.0
000284822 0247_ $$2doi$$a10.1038/s41598-023-43049-2
000284822 0247_ $$2pmid$$apmid:37857656
000284822 0247_ $$2altmetric$$aaltmetric:155637001
000284822 037__ $$aDKFZ-2023-02118
000284822 041__ $$aEnglish
000284822 082__ $$a600
000284822 1001_ $$00000-0003-2157-9333$$aHoppner, Jorge$$b0
000284822 245__ $$aComparison of early and late 68Ga-FAPI-46-PET in 33 patients with possible recurrence of pancreatic ductal adenocarcinomas.
000284822 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2023
000284822 3367_ $$2DRIVER$$aarticle
000284822 3367_ $$2DataCite$$aOutput Types/Journal article
000284822 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726648870_14745
000284822 3367_ $$2BibTeX$$aARTICLE
000284822 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284822 3367_ $$00$$2EndNote$$aJournal Article
000284822 520__ $$aPositron emission tomography with 68Gallium (68Ga) labeled inhibitors of fibroblast activation protein (68Ga-FAPI-PET) is a promising imaging technique for patients with recurrent pancreatic ductal adenocarcinomas (PDAC). To date, it is not clear if different acquisition timepoints for 68Ga-FAPI-PET may result in comparable imaging information and if repetitive 68Ga-FAPI-PET imaging may add diagnostic value to single timepoint acquisition for recurrent PDAC. Here we analyzed retrospectively early (20 min p.i.) and late (60 min p.i.) 68Ga-FAPI-PET imaging using FAPI-46 of 33 patients with possible recurrence of PDAC concerning detection rates and uptake over time of local recurrences, metastases, inflammatory lesions of the pancreas, cholestatic lesions of the liver and reactive tissue. 33 patients with histologically confirmed PDAC after complete or partial resection of the pancreas and possible recurrence were examined by 68Ga-FAPI-46-PET acquired 20- and 60-min post injection (p.i.) of the radiotracer. FAPI-positive lesions were classified as local recurrences, metastases, inflammatory lesions of the pancreas (ILP), cholestatic lesions of the liver and reactive tissue based on histology, PET- and CT-morphology and clinical information. Lesions were contoured, and standardized uptake values (SUVmax and SUVmean) and target-to-background ratios (TBR) were analyzed for both acquisition timepoints. In total, 152 FAPI-positive lesions (22 local relapses, 47 metastases, 26 inflammatory lesions of the pancreas, 28 reactive tissues, and 29 cholestatic lesions) were detected. Detection rates for the early and late acquisition of 68Ga-FAPI-46-PET were almost identical except cholestatic lesions, which showed a higher detection rate at early imaging. SUV parameters and TBRs of ILP significantly decreased over time. Cholestatic lesions showed a tendency towards decreasing uptake. All other types of lesions showed relatively stable uptake over time. Early and late acquisition of 68Ga-FAPI-PET results in comparable imaging information in patients with possible recurrence of PDAC. Two timepoint imaging offers additional diagnostic potential concerning differential diagnoses.
000284822 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000284822 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284822 7001_ $$avan Genabith, Levin$$b1
000284822 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2$$udkfz
000284822 7001_ $$aHeger, Ulrike$$b3
000284822 7001_ $$aSperling, Lucas$$b4
000284822 7001_ $$aColbatzky, Teresa$$b5
000284822 7001_ $$aGutjahr, Ewgenija$$b6
000284822 7001_ $$aLang, Matthias$$b7
000284822 7001_ $$aPausch, Thomas$$b8
000284822 7001_ $$aSpektor, Anna-Maria$$b9
000284822 7001_ $$0P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aGlatting, Frederik M$$b10$$udkfz
000284822 7001_ $$aLiermann, Jakob$$b11
000284822 7001_ $$aHackert, Thilo$$b12
000284822 7001_ $$aKratochwil, Clemens$$b13
000284822 7001_ $$aGiesel, Frederik L$$b14
000284822 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b15$$udkfz
000284822 7001_ $$00000-0001-7609-243X$$aRöhrich, Manuel$$b16
000284822 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-023-43049-2$$gVol. 13, no. 1, p. 17848$$n1$$p17848$$tScientific reports$$v13$$x2045-2322$$y2023
000284822 909CO $$ooai:inrepo02.dkfz.de:284822$$pVDB
000284822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000284822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1fc3c2327d9c213c36fe740ef63e1baa$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000284822 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000284822 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000284822 9141_ $$y2023
000284822 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:06Z
000284822 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:06Z
000284822 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:06Z
000284822 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-04-12T15:11:06Z
000284822 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000284822 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000284822 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000284822 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000284822 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x2
000284822 980__ $$ajournal
000284822 980__ $$aVDB
000284822 980__ $$aI:(DE-He78)C060-20160331
000284822 980__ $$aI:(DE-He78)E055-20160331
000284822 980__ $$aI:(DE-He78)E060-20160331
000284822 980__ $$aUNRESTRICTED